The purpose of the study was to examine the capacity of AEFI surveillance during immunisation campaigns using the novel conjugate meningitis vaccine (MenAfrivac). A comprehensive review of Menafrivac studies published in English between 2001 and 2016 was conducted. The incidence of AEFIs (I) was calculated and compared utilising the incidence difference between MenAfrivacTM clinical trials and vaccination programmes (Id). There were nine studies included, with a total local AEFI I of 11,496/100,000 doses provided per week in clinical trials and 0.72/100,000 doses administered in vaccination campaigns.
In clinical studies, an Id of 11,497.92 [11,497.91-11,497.93] and 17,243.20 [17,241.80-17,245.90] per 100,000 doses delivered per week for total local and systemic AEFI, respectively, were reported. The occurrence of AEFIs following Menafrivac immunisation was much lower in campaigns than in clinical trial trials. The current capability of AEFI surveillance during vaccination campaigns necessitates a thorough re-evaluation of its structure and capabilities.
Reference: https://www.tandfonline.com/doi/full/10.1080/21645515.2019.1652041
